Lv4
676 积分 2026-01-11 加入
Therapeutic targeting of mismatch repair-deficient cancers
3天前
已完结
Pembrolizumab, PD-1 Blocking Immune Checkpoint Inhibitor, for the Management of Periocular Sebaceous Carcinoma
17天前
已关闭
IL-17A-secreting γδ T cells promote resistance to CDK4/CDK6 inhibitors in HR+HER2- breast cancer via CX3CR1+ macrophages
17天前
已完结
Immunotherapy in synchronous gastric and colonic deficient mismatch repair malignancies in a case series of patients with Lynch syndrome
17天前
已关闭
Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial
17天前
已完结
Mismatch Repair Proficient Colorectal Adenocarcinoma in Two Patients With Lynch Syndrome
17天前
已完结
Dual mechanism of immune escape shapes the genetic and immunogenic landscape of mismatch repair-deficient colorectal tumours
17天前
已关闭
Organ-sparing strategies in patients with MSI/dMMR tumors including Lynch syndrome: Current state of the art and future perspectives for clinical decision-making
17天前
已关闭
Targeting HSPB1 inhibits tumor growth and abrogates Treg-mediated tumor immunosuppression
17天前
已完结
Antiangiogenic-immune-checkpoint inhibitor combinations: lessons from phase III clinical trials
17天前
已完结
皖公网安备34019202002308
